Open AccessP1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY
Author(s) -
Matasar M.,
Bartlett N. L.,
Sehn L. H.,
Schuster S. J.,
Assouline S.,
Giri P.,
Kuruvilla J.,
Canales M.,
Dietrich S.,
Fay K.,
Ku M.,
Nastoupil L. J.,
Wei M. C.,
Yin S.,
To I.,
Turner D.,
Huang H.,
Min J.,
Penuel E.,
Budde L. E.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847372.57687.d4
Subject(s) - medicine , follicular lymphoma , gastroenterology , clinical endpoint , rituximab , tolerability , dosing , phases of clinical research , refractory (planetary science) , lymphoma , adverse effect , clinical trial , oncology , physics , astrobiology